In support of the supposition, our data using paraffin-embedded tissues from HNSCC patients in a cixutumumab clinical trial showed significant increases in tumour-associated macrophages, cancer-associated fibroblasts, VE cells and IGF-2 expression. The gene discussed is IGF2; the disease is head and neck squamous cell carcinoma.